Peptide News Digest

#Fap

3 stories

Research · View digest

Chinese Team's Sugar-Modified FAP-Targeting Peptide Tracer Shows About Five Times the Tumor Uptake of FAP-2286 in Mice

Researchers from the Chinese Academy of Sciences and Southern Medical University reported in the Journal of Medicinal Chemistry on October 20, 2026 FAP-Man, a mannose-modified version of the FAP-2286 peptide scaffold that targets fibroblast activation protein, which is abundant in tumor-associated fibroblasts. In mice with U87MG tumors, the gallium-68 version reached 16.9% of the injected dose per gram of tumor at one hour versus 3.2% for gallium-68 FAP-2286, with better tumor-to-liver contrast, and lutetium-177 and actinium-225 versions slowed tumor growth compared with saline. The authors describe preliminary clinical PET scans as supportive but give no patient numbers in the abstract.

Research · View digest

Avacta AVA6103 Peptide-Drug Conjugate Shows 3x Tumor Selectivity vs Enhertu in Preclinical Data

Avacta Therapeutics presented April 21 data at AACR 2026 showing its FAP-enabled peptide-drug conjugate AVA6103, which delivers exatecan via the pre|CISION® platform, achieved a Tumor Selectivity Index three times higher than marketed ADC Enhertu in preclinical models, with tumor Cmax more than one log higher. AVA6103 entered the Phase 1 FOCUS-01 trial (NCT07454642) in March 2026 with initial clinical readout expected later this year.

Research · View digest

AlphaGen's [212Pb]Pb-AG1206 Macrocyclic Peptide Radioligand Targets FAP in Solid Tumors

AlphaGen Therapeutics presented preclinical data at AACR 2026 (April 22) showing its novel macrocyclic peptide-based alpha-emitter radioligand [212Pb]Pb-AG1206 binds fibroblast activation protein with picomolar affinity, achieving rapid tumor accumulation, renal clearance, and a high tumor-to-kidney ratio. A sister candidate [212Pb]Pb-AG1002 targets SSTR2 as a non-agonist alpha therapy for neuroendocrine tumors.